The systemic inflammation response index: An independent predictive factor for survival outcomes of bladder cancer stronger than other inflammatory markers

Yılmaz, Hasan; Cinar, Naci Burak; Avcı, İbrahim Erkut; Telli, Engin; Uslubas, Ali K; Teke, Kerem; Dillioğlugil, Özdal

doi:10.1016/j.urolonc.2022.11.011

Cited by 7 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The systemic inflammatory response has been shown to promote cancer progression and contribute to different stages of tumor development, including initiation, invasion, angiogenesis, and metastasis (42). In recent years, the association between the SII and the prognosis of various cancer types has been extensively investigated, demonstrating its potential as a prognostic indicator, particularly for predicting survival outcomes in patients with malignant tumors (16,17,(19)(20)(21)(22)(23)(24)(25)27). SII has been identified as a valuable prognostic indicator for numerous solid tumors, including hepatocellular carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, gastric cancer, laryngeal cancer, endometrial cancer, non-small cell lung cancer, and bladder cancer, among others.…”

Section: Discussionmentioning

confidence: 99%

“…Initial reports have shown that SII can predict the prognosis of patients with hepatocellular carcinoma after radical resection, and it has been identified as a powerful prognostic indicator for poor prognosis in hepatocellular carcinoma patients (15,16). Subsequent studies have confirmed its effectiveness in predicting the prognosis of various cancer patients, including hepatocellular carcinoma (16), pancreatic cancer (17), gallbladder cancer (18), cholangiocarcinoma (19), gastric cancer (20), laryngeal cancer (21), endometrial cancer (22), non-small cell lung cancer (23), and bladder cancer (24). In recent years, the prognostic value of SII in urological system cancers has been investigated and confirmed by many researchers, although the conclusions are not entirely consistent (25)(26)(27)(28).…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Prognostic and clinical pathological significance of the systemic immune-inflammation index in urothelial carcinoma: a systematic review and meta-analysis

Wang,

Hao,

2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundA new non-invasive biomarker, the Systemic Immune-Inflammation Index (SII), has been proven to have prognostic value in multiple cancers. This systematic review and meta-analysis aimed to investigate the prognostic and clinical pathological significance of SII in urothelial carcinoma.MethodsA comprehensive search was conducted across multiple databases, including PubMed, Web of Science, Embase, Cochrane Library, and CNKI. The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). Hazard ratios (HR) with 95% confidence intervals (CI) were calculated to evaluate the prognostic value of SII before treatment on survival outcomes, and odds ratios (OR) with 95%CI were used to assess the correlation between SII before treatment and clinical pathological features.ResultsThis meta-analysis included a total of 10 studies (11 datasets) with 6,333 patients. The pooled analysis showed that high SII before surgery was significantly associated with poor survival outcomes in patients with urothelial carcinoma, including overall survival (OS) (HR=1.55, 95%CI 1.24-1.95, p<0.001), cancer-specific survival (CSS) (HR=2.74, 95%CI 1.67-4.49, p<0.001), recurrence-free survival (RFS) (HR=2.74, 95%CI 1.67-4.49, p<0.001), and progression-free survival (PFS) (HR=1.66, 95%CI 1.36-2.02, p<0.001). In addition, patients with elevated preoperative SII values were more likely to have adverse pathological features, including larger tumor size and advanced pathological T stage (p<0.001).ConclusionThese findings suggest a significant association between high SII levels before treatment and poor survival outcomes, as well as certain clinical pathological features, in patients with urothelial carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

Prognostic and clinical pathological significance of the systemic immune-inflammation index in urothelial carcinoma: a systematic review and meta-analysis

Wang,

Hao,

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The systemic inflammation response index (SIRI) is a novel hematologic parameter that was first proposed in 2016 ( 12 ) and is determined using the following formula: SIRI = (neutrophil × monocyte)/lymphocyte count. SIRI has been widely suggested to exhibit a significant and powerful value in predicting solid tumors such as bladder cancer ( 13 ), non-small cell lung cancer (NSCLC) ( 14 ), gastric cancer ( 15 ), breast cancer ( 16 ), and ovarian cancer ( 17 ). The impact of the SIRI on predicting HCC prognosis has also been explored; however, no consistent findings have been found ( 18 – 27 ).…”

Section: Introductionmentioning

confidence: 99%

Prognostic and clinicopathological significance of systemic inflammation response index in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Zhang,

Tang

2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundIt is unclear whether the systemic inflammation response index (SIRI) can predict the prognosis of patients with hepatocellular carcinoma (HCC). Consequently, the present study focused on systematically identifying the relationship between SIRI and the prognosis of patients with HCC through a meta-analysis.MethodsSystematic and comprehensive studies were retrieved from PubMed, Web of Science, Embase, and the Cochrane Library from their inception to August 10, 2023. The role of SIRI in predicting overall survival (OS) and progression-free survival (PFS) in HCC was determined using pooled hazard ratios (HRs) and 95% confidence intervals (CIs). Odds ratios (ORs) and 95% CIs were pooled to analyze the correlations between SIRI and the clinicopathological features of HCC.ResultsTen articles involving 2,439 patients were included. An elevated SIRI was significantly associated with dismal OS (HR=1.75, 95% CI=1.52–2.01, p<0.001) and inferior PFS (HR=1.66, 95% CI=1.34–2.05, p<0.001) in patients with HCC. Additionally, according to the combined results, the increased SIRI was significantly related to multiple tumor numbers (OR=1.42, 95% CI=1.09–1.85, p=0.009) and maximum tumor diameter >5 cm (OR=3.06, 95% CI=1.76–5.30, p<0.001). However, the SIRI did not show any significant relationship with sex, alpha-fetoprotein content, Child-Pugh class, or hepatitis B virus infection.ConclusionAccording to our results, elevated SIRI significantly predicted OS and PFS in patients with HCC. Moreover, the SIRI was significantly associated with tumor aggressiveness.Systematic review registrationhttps://inplasy.com/inplasy-2023-9-0003/, identifier INPLASY202390003.

show abstract

“…Indices such as the neutrophil to lymphocyte ratio (NLR), systemic inflammation response index (SIRI), and the systemic immune inflammation index (SIII) have all been independently associated with in-hospital mortality in critically ill patients with cerebral infarction (8)(9)(10). However, including these highly correlated composite hematological indices in survival analysis models simultaneously can lead to common issues like multicollinearity, complicating their interpretation and potentially weakening the model's overall predictive accuracy (11)(12)(13). To overcome this issue, our study implemented a novel, data-driven approach.…”

Section: Introductionmentioning

confidence: 99%

Exploring the utility of a latent variable as comprehensive inflammatory prognostic index in critically ill patients with cerebral infarction

Shu,

Zheng,

Zhang

2024

Front. Neurol.

View full text Add to dashboard Cite

ObjectiveWe introduce the comprehensive inflammatory prognostic index (CIPI), a novel prognostic tool for critically ill cerebral infarction patients, designed to meet the urgent need for timely and convenient clinical decision-making in this high-risk patient group.MethodsUsing exploratory factor analysis on selected indices—neutrophil to lymphocyte ratio (NLR), systemic inflammation response index (SIRI), and systemic immune inflammation index (SIII)—we derived CIPI, a latent variable capturing their combined predictive power. Data from 1,022 patients in the Medical Information Mart for Intensive Care (MIMIC)-IV database were used to develop CIPI-based survival models, with the robustness and area under the receiver operating characteristic curve (AUC) performance of CIPI validated against an independent dataset of 326 patients from the MIMIC-III CareVue subset. The CIPI’s predictive power for in-hospital and intensive care unit (ICU) mortality was assessed through Kaplan–Meier analysis, univariate and multivariate Cox regression models, and time-dependent AUC analysis. Linearity, subgroup sensitivity analyses and interaction effects with CIPI were also evaluated.ResultsCIPI was an independent prognostic factor, demonstrating a statistically significant association with in-hospital and ICU mortality, when assessed as a continuous and a categorical variable. It showed a linear relationship with mortality rates and demonstrated stability across most subgroups, with no significant interactions observed. Its predictive capabilities for in-hospital and ICU mortality among critically ill cerebral infarction patients matched those of established prognostic indices in the MIMIC database.ConclusionOur study indicates that CIPI is a reliable and effective prognostic tool for critically ill cerebral infarction patients in predicting in-hospital and ICU mortality. Its straightforward calculation, rooted in routine blood tests, enhances its practicality, promising significant utility in clinical settings.

show abstract

The systemic inflammation response index: An independent predictive factor for survival outcomes of bladder cancer stronger than other inflammatory markers

Cited by 7 publications

References 20 publications

Prognostic and clinical pathological significance of the systemic immune-inflammation index in urothelial carcinoma: a systematic review and meta-analysis

Prognostic and clinical pathological significance of the systemic immune-inflammation index in urothelial carcinoma: a systematic review and meta-analysis

Prognostic and clinicopathological significance of systemic inflammation response index in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Exploring the utility of a latent variable as comprehensive inflammatory prognostic index in critically ill patients with cerebral infarction

Contact Info

Product

Resources

About